NorthRock Partners’s Acceleron Pharma XLRN Stock Holding History

NorthRock Partners’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,200	Closed	-$379K	–	365
2021 Q3	$379K	Hold	2,200	–	–	0.03%	188
2021 Q2	$276K	Hold	2,200	–	–	0.02%	202
2021 Q1	$298K	Hold	2,200	–	–	0.03%	177
2020 Q4	$281K	Sell	2,200 -800	-27%	-$93.8K	0.03%	181
2020 Q3	$338K	Sell	3,000 -2	-0.1%	-$199	0.04%	149
2020 Q2	$286K	Buy	3,002 +502	+20%	+$48.4K	0.03%	160
2020 Q1	$225K	Buy	+2,500	New	+$194K	0.03%	172

NorthRock Partners's XLRN Position: Q4 2021 in Review

NorthRock Partners sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 2,200 shares — an estimated $379K sold.

NorthRock Partners first reported a position in XLRN in Q1 2020 and held it in 7 quarters. The position peaked at $379K in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

NorthRock Partners reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
NorthRock Partners sold 2,200 Acceleron Pharma shares in Q4 2021, an estimated $379K.
NorthRock Partners first reported a position in Acceleron Pharma in Q1 2020 and held it in 7 quarters.
NorthRock Partners's Acceleron Pharma position peaked at $379K in Q3 2021.
1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on NorthRock Partners's 13F filing for Q4 2021, filed 7 Feb 2022.